[
  {
    "ts": null,
    "headline": "Why IDEX (IEX) Is Up 8.1% After Q4 Earnings Beat And Record AI-Linked Orders",
    "summary": "IDEX Corporation has already reported fourth-quarter and full-year 2025 results, with Q4 sales rising to US$899.1 million and net income to US$128.3 million, while full-year sales increased to US$3.46 billion even as annual net income eased to US$483.2 million. The company outpaced analyst expectations and highlighted record organic order growth in its Health and Science Technology segment, supported by demand from data centers and AI-related ecosystems. We’ll examine how IDEX’s earnings...",
    "url": "https://finnhub.io/api/news?id=ff93bbd9d63f6e0cb69a145d983b807cb0a169a0e304acd657e60ea9e39d5ef6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770301047,
      "headline": "Why IDEX (IEX) Is Up 8.1% After Q4 Earnings Beat And Record AI-Linked Orders",
      "id": 138364748,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "IEX",
      "source": "Yahoo",
      "summary": "IDEX Corporation has already reported fourth-quarter and full-year 2025 results, with Q4 sales rising to US$899.1 million and net income to US$128.3 million, while full-year sales increased to US$3.46 billion even as annual net income eased to US$483.2 million. The company outpaced analyst expectations and highlighted record organic order growth in its Health and Science Technology segment, supported by demand from data centers and AI-related ecosystems. We’ll examine how IDEX’s earnings...",
      "url": "https://finnhub.io/api/news?id=ff93bbd9d63f6e0cb69a145d983b807cb0a169a0e304acd657e60ea9e39d5ef6"
    }
  },
  {
    "ts": null,
    "headline": "Is It Too Late To Reassess IDEX (IEX) After Its Recent Share Price Surge?",
    "summary": "Wondering if IDEX at around US$212 per share is offering good value right now, or if the recent strength already reflects what it is worth. The stock has moved sharply in the short term, with returns of 8.1% over the last 7 days, 17.4% over the last 30 days, and 18.5% year to date, compared with 9.1% over 1 year, negative 1.6% over 3 years, and 13.3% over 5 years. Recent price moves have come as investors refocus on IDEX as an established name in the capital goods space and reconsider how it...",
    "url": "https://finnhub.io/api/news?id=31b784960aa09f3f3bb9f0bb2471f44a1b9ef5054265312b4be2ad9d5064f652",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770296934,
      "headline": "Is It Too Late To Reassess IDEX (IEX) After Its Recent Share Price Surge?",
      "id": 138363787,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "IEX",
      "source": "Yahoo",
      "summary": "Wondering if IDEX at around US$212 per share is offering good value right now, or if the recent strength already reflects what it is worth. The stock has moved sharply in the short term, with returns of 8.1% over the last 7 days, 17.4% over the last 30 days, and 18.5% year to date, compared with 9.1% over 1 year, negative 1.6% over 3 years, and 13.3% over 5 years. Recent price moves have come as investors refocus on IDEX as an established name in the capital goods space and reconsider how it...",
      "url": "https://finnhub.io/api/news?id=31b784960aa09f3f3bb9f0bb2471f44a1b9ef5054265312b4be2ad9d5064f652"
    }
  },
  {
    "ts": null,
    "headline": "IDEX Q4 Earnings Call Highlights",
    "summary": "IDEX (NYSE:IEX) executives said the company closed fiscal 2025 with “better-than-expected” fourth-quarter results, led by accelerating demand in its Health & Science Technologies (HST) segment and continued progress on its “purposeful evolution” strategy anchored by 80/20 practices and platform-",
    "url": "https://finnhub.io/api/news?id=97c3176133a469da657e4d2982be6e77cb840176bab921ebed2e4f0184e4f3e0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770280016,
      "headline": "IDEX Q4 Earnings Call Highlights",
      "id": 138362168,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "IEX",
      "source": "Yahoo",
      "summary": "IDEX (NYSE:IEX) executives said the company closed fiscal 2025 with “better-than-expected” fourth-quarter results, led by accelerating demand in its Health & Science Technologies (HST) segment and continued progress on its “purposeful evolution” strategy anchored by 80/20 practices and platform-",
      "url": "https://finnhub.io/api/news?id=97c3176133a469da657e4d2982be6e77cb840176bab921ebed2e4f0184e4f3e0"
    }
  },
  {
    "ts": null,
    "headline": "IEX Q4 Deep Dive: Data Center Demand and HST Segment Drive Outperformance",
    "summary": "Manufacturing company IDEX (NYSE:IEX) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 4.2% year on year to $899.1 million. Its non-GAAP profit of $2.10 per share was 2.9% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=47caf7869d84be1481dfd3688af9363b90da4a517623a9c836f2f06a14d8ab48",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770269925,
      "headline": "IEX Q4 Deep Dive: Data Center Demand and HST Segment Drive Outperformance",
      "id": 138362870,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "IEX",
      "source": "Yahoo",
      "summary": "Manufacturing company IDEX (NYSE:IEX) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 4.2% year on year to $899.1 million. Its non-GAAP profit of $2.10 per share was 2.9% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=47caf7869d84be1481dfd3688af9363b90da4a517623a9c836f2f06a14d8ab48"
    }
  }
]